Assisted Reproductive Technology Market Report 2026

Assisted Reproductive Technology Market Overview

• Assisted Reproductive Technology market size has reached to $37.06 billion in 2025 • Expected to grow to $56.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Infertility Cases Fuelling The Growth Of Assisted Reproductive Technology Market • Market Trend: New Reproductive Health Solutions Broaden Pgt-A Alternatives • Europe was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Assisted Reproductive Technology Market?

Assisted reproductive technology is based on the surgical removal of eggs from women’s ovaries and then fusing them with men’s sperm in the laboratory to create embryos. These embryos are then inserted back into the woman’s body. ART uses donor eggs, donor sperm, or previously stored frozen embryos. Assisted reproductive technology (ART) is used for the treatment of infertility in either eggs or embryos. The main types of assisted reproductive technology are in-vitro fertilization (IVF), artificial insemination (AI-IUI), frozen embryo replacement (FER), and others. In-vitro fertilisation (IVF) is a complicated operation that involves collecting eggs and fertilising them with sperm in a lab to create embryos. These embryos are subsequently implanted into women's reproductive organs. The different procedure types include fresh non-donor, fresh donor, frozen donor, frozen non donor, embryo or egg banking and is used in hospitals, fertility clinics, others.

What Is The Assisted Reproductive Technology Market Growth Forecast?

The assisted reproductive technology market size is expected to see strong growth in the next few years. It will grow to $56.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing adoption of precision fertility diagnostics, rising investments in fertility treatment infrastructure, expansion of genetic testing applications, growing demand for minimally invasive procedures, increasing healthcare spending on reproductive health. Major trends in the forecast period include increasing adoption of advanced embryo screening techniques, rising use of frozen embryo and egg banking, growing demand for personalized fertility treatments, expansion of genetic testing in art procedures, enhanced focus on treatment success rates.

Global Assisted Reproductive Technology Market Segmentation

1) By Diagnosis: Hysterosalpingography, Ovarian Reserve Testing, Genetic Testing 2) By Procedure Type: Fresh Non-Donor, Fresh Donor, Frozen Donor, Frozen Non-Donor, Embryo Or Egg Banking 3) By End-User: Hospitals, Fertility Clinics, Other End-Users Subsegments: 1) By Hysterosalpingography (HSG): X-ray HSG, Sonohysterography (SHG) 2) By Ovarian Reserve Testing: Follicle Stimulating Hormone (FSH) Testing, Anti-Müllerian Hormone (AMH) Testing, Antral Follicle Count (AFC) via Ultrasound 3) By Genetic Testing: Preimplantation Genetic Testing (PGT), Carrier Screening Tests, Genetic Compatibility Testing

What Is The Driver Of The Assisted Reproductive Technology Market?

The rising number of infertility cases is expected to foster the assisted reproductive technology market in the coming years. Infertility is defined as the failure to become pregnant after a year of frequent and unprotected intercourse. Infertility affects both men and women and is typically diagnosed by the inability to conceive. Infertility is treated using assisted reproductive technology (ART). Fertility therapies that work with both a woman's egg and a man's sperm are included in this. For instance, in April 2023, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people in the world who are of reproductive age will struggle with infertility, which will also influence their families and communities. Worldwide, it is estimated that 1 in 6 adults, or around 17.5% of the global adult population, struggle with infertility. Therefore, the rising number of infertility cases drives the growth of the assisted reproductive technology industry.

Key Players In The Global Assisted Reproductive Technology Market

Major companies operating in the assisted reproductive technology market are Cooper Surgical Inc., Ferring Pharmaceuticals Ltd., Hamilton Thorne Ltd., Merck KGaA, Genea Limited, California Cryobank, European Sperm Bank, OvaScience Inc., Bloom IVF Centre, Vitrolife AB, FUJIFILM Irvine Scientific Inc., Nidacon International AB, Monash IVF Group Ltd., Cook Medical, INVO Bioscience Inc., Thermo Fisher Scientific Inc., Anecova Sa, Carolinas Fertility Institute, Microm Ltd., Inception Sciences Inc., Progyny Inc., Oxford Gene Technology IP Ltd., IVI-RMA Global, Boston IVF, CARE Fertility Group, Virtus Health, Reproductive Medicine Associates of New York, Shady Grove Fertility, CCRM Fertility, New Hope Fertility Center, Houston Fertility Institute, Pacific Fertility Center, RMA of New Jersey, Sher Fertility Institute, IVF Florida, ORM Fertility, HRC Fertility, Arizona Center for Reproductive Endocrinology & Infertility, San Diego Fertility Center, Fertility Centers of Illinois

Global Assisted Reproductive Technology Market Trends and Insights

Major companies operating in the assisted reproductive technology market are focusing on developing advanced solutions, such as next-generation sequencing (NGS)-based testing kits, to improve chromosomal analysis, enhance embryo selection, and increase the success rates of fertility treatments. NGS-based preimplantation genetic testing refers to research-use technologies that enable comprehensive assessment of chromosomal abnormalities in embryos, supporting informed decision-making during IVF and ICSI procedures. For instance, in July 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, launched two next-generation sequencing-based products the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit to support preimplantation genetic testing for aneuploidy (PGT-A). Designed for reproductive health laboratories, these assays are the first research-use products of their kind and are compatible with the Ion Torrent Genexus Integrated Sequencer, enabling a streamlined workflow from sample processing to aneuploidy analysis. PGT-A testing helps identify chromosomal abnormalities in embryo samples, and these new solutions aim to advance scientific understanding, improve pregnancy success rates, and promote healthier outcomes for future generations. The Genexus platform further simplifies the research process through integrated templating, sequencing, and data analysis, while the Ion AmpliSeq Polyploidy Panel kit offers enhanced quality control features to detect contamination, avoid sample mix-ups, and identify triploidy in embryos, reinforcing technological progress within the assisted reproductive technology market.

What Are Latest Mergers And Acquisitions In The Assisted Reproductive Technology Market?

In November 2023, CooperCompanies, a US-based medical device company, acquired Cook Medical's Reproductive Health business for a deal of $300 million. The acquired products complement CooperSurgical’s existing portfolio of medical devices and enhance the company's position as a leading global provider in fertility and women’s health. Cook Medical is a US-based provider of assisted reproductive technology.

Regional Outlook

Europe was the largest region in the assisted reproductive technology market in 2025. North America was the second-largest region in assisted reproductive technology market. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Assisted Reproductive Technology Market?

The assisted reproductive technology market includes revenues earned by entities by gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and frozen embryo transfer (FET). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Assisted Reproductive Technology Market Report 2026?

The assisted reproductive technology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the assisted reproductive technology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.